BioAge Labs (NASDAQ:BIOA) used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant inhibitor of the NLRP3 inflammasome that the company is developing across cardiovascular...
Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk Phase 2 dose-ranging proof-of-concept...
Barchart Research What to Expect from BIOA Earnings BIOA Generated May 4, 2026 Current Price $16.62 EPS Estimate $$-0.71 Consensus Rating Moderate Buy Average Move 6.27% Can BioAge Labs Break Its Pattern...
Live webcast on Friday, May 8, 2026, beginning at 12:30 PM ET Event will feature Phase 1 clinical data for BGE-102 and the therapeutic rationale for development in atherosclerotic cardiovascular disease...
120 mg and newly announced 60 mg once-daily doses each achieved ≥85% median hsCRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all...
EMERYVILLE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for...
Barchart Research What to Expect from BIOA Earnings BIOA Generated March 25, 2026 Current Price $16.41 EPS Estimate $-0.74 Consensus Rating Moderate Buy Average Move 4.45% Bioage Labs Faces Widening Losses...
Positive interim Phase 1 data for BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor, demonstrating potential best-in-class reductions in inflammatory...
EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for...
EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates...